ZyVersa Therapeutics (NASDAQ:ZVSA) Rating Increased to Hold at Wall Street Zen

ZyVersa Therapeutics (NASDAQ:ZVSA) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

ZyVersa Therapeutics Price Performance

Shares of ZyVersa Therapeutics stock opened at $0.59 on Friday. The firm’s 50 day moving average price is $0.62 and its 200-day moving average price is $0.89. ZyVersa Therapeutics has a 52-week low of $0.47 and a 52-week high of $5.34.

ZyVersa Therapeutics (NASDAQ:ZVSA) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.33). On average, equities research analysts forecast that ZyVersa Therapeutics will post -22.7 EPS for the current fiscal year.

Hedge Funds Weigh In On ZyVersa Therapeutics

A hedge fund recently bought a new stake in ZyVersa Therapeutics stock. Virtu Financial LLC purchased a new position in shares of ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 25,259 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned 1.08% of ZyVersa Therapeutics at the end of the most recent reporting period. Institutional investors own 3.91% of the company’s stock.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.